Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer

Oncogene. 1997 Jul 31;15(5):579-84. doi: 10.1038/sj.onc.1201216.

Abstract

Head and neck squamous cell cancers (HNSCC) have a high local recurrence rate due to incomplete tumor resection. The use of molecular markers to establish surgical margins may decrease local recurrence. Surgical margins are determined by histopathologic analysis on frozen sections. We postulate that genetic and molecular changes precede gross histologic alterations. Tumor markers may improve the reliability of pathology examination, but those evaluated to date lack the sensitivity needed for routine clinical use. Western blot analysis showed elevated eIF4E in all 26 HNSCC in contrast to its low expression in benign lesions. Surgical margins were analysed for eIF4E in 23 patients. Twelve patients showed elevated eIF4E in histologically negative margins. Cancer has recurred in 5 of the 12 patients as opposed to none of the 11 patients with eIF4E negative margins (P= 0.02, Log rank test). This is the first report of eIF4E in HNSCC, as a sensitive and specific marker for HNSCC, with potential for defining clear resection margins. The correlation between elevated levels of eIF4E at the margins and recurrence highlights its ability to detect malignant cells prior to clear-cut alterations in morphology. The accuracy and simplicity of these assays underscore the usefulness of eIF4E in managing HNSCC.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Blotting, Western
  • Eukaryotic Initiation Factor-4E
  • Female
  • Head and Neck Neoplasms / genetics*
  • Head and Neck Neoplasms / pathology
  • Head and Neck Neoplasms / surgery*
  • Humans
  • Male
  • Middle Aged
  • Peptide Initiation Factors / analysis
  • Peptide Initiation Factors / genetics
  • Peptide Initiation Factors / metabolism*
  • Predictive Value of Tests
  • Proto-Oncogene Mas
  • Recurrence
  • Treatment Outcome

Substances

  • Eukaryotic Initiation Factor-4E
  • MAS1 protein, human
  • Peptide Initiation Factors
  • Proto-Oncogene Mas